Items where authors include "Faust, S.N."

Article

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Sandercock, P., Darbyshire, J., DeMets, D. et al. (2050 more authors) (2024) Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Nature Communications, 15. 924. ISSN 2041-1723

Shaw, R.H., Greenland, M., Stuart, A.S.V. et al. (37 more authors) (2023) Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines. Journal of Infection, 86 (6). pp. 574-583. ISSN 0163-4453

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Mentzer, A.J. orcid.org/0000-0002-4502-2209, O’Connor, D. orcid.org/0000-0002-6902-9886, Bibi, S. et al. (66 more authors) (2023) Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection. Nature Medicine, 29 (1). pp. 147-157. ISSN 1078-8956

Shaw, R.H., Liu, X., Stuart, A.S.V. et al. (81 more authors) (2022) Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. The Lancet Respiratory Medicine, 10 (11). pp. 1049-1060. ISSN 2213-2600

Stuart, A.S.V., Shaw, R.H., Liu, X. et al. (40 more authors) (2022) Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. The Lancet, 399 (10319). pp. 36-49. ISSN 0140-6736

de Graaf, H., Payne, R.O. orcid.org/0000-0002-8490-671X, Taylor, I. et al. (25 more authors) (2021) Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. Frontiers in Immunology, 12. 694759.

Minassian, A.M., Silk, S.E., Barrett, J.R. et al. (47 more authors) (2021) Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med, 2 (6). 701-719.e19. ISSN 2666-6340

Ramasamy, M.N., Minassian, A.M., Ewer, K.J. et al. (418 more authors) (2020) Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet, 396 (10267). pp. 1979-1993. ISSN 0140-6736

Rampling, T., Ewer, K.J., Bowyer, G. et al. (32 more authors) (2018) Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. npj Vaccines, 3 (1). 49. ISSN 2059-0105

Coughlan, L., Sridhar, S., Payne, R. orcid.org/0000-0002-8490-671X et al. (16 more authors) (2018) Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. EBioMedicine, 29. pp. 146-154. ISSN 2352-3964

Payne, RO orcid.org/0000-0002-8490-671X, Silk, SE, Elias, SC et al. (39 more authors) (2017) Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions. JCI insight, 2 (21). e96381. ISSN 2379-3708

Coulter, T.I., Chandra, A., Bacon, C.M. et al. (55 more authors) (2017) Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study. Journal of Allergy and Clinical Immunology, 139 (2). 597-606.e4. ISSN 0091-6749

Rampling, T., Ewer, K.J., Bowyer, G. et al. (28 more authors) (2016) Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. Journal of infectious diseases, 214 (5). pp. 772-781. ISSN 0022-1899

Payne, R.O. orcid.org/0000-0002-8490-671X, Milne, K.H., Elias, S.C. et al. (35 more authors) (2016) Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01. The Journal of infectious diseases, 213 (11). pp. 1743-1751. ISSN 0022-1899